Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 4/5/2024
The Providers Clinical Support System - Medications for Alcohol Use Disorder (PCSS-MAUD) is a national project funded by the Substance Abuse and Mental Health Services Administration to provide free, comprehensive training, guidance, and mentoring on the prevention, diagnosis, and treatment of alcohol use disorder.
Posted 3/10/2021 (updated 4/5/2024)
The 2020 National Drug Threat Assessment (NDTA) is a comprehensive assessment of the threat posed to the United States by the trafficking and abuse of illicit drugs, the diversion and abuse of licit drugs, and the laundering of proceeds generated through illicit drug sales. It also addresses the role domestic groups, including organized violent gangs, serve in domestic drug trafficking. The most widely trafficked drugs are discussed in terms of their availability, consumption and overdose related deaths, production and cultivation, transportation, and distribution.
Posted 3/2/2021 (updated 4/5/2024)
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 10/19/2020 (updated 3/29/2024)
The Providers Clinical Support System (PCSS) Mentoring Program support is recommended for clinicians who are contemplating or have recently begun prescribing MOUD and would like additional support. PCSS offers three tiers of service at no cost to the recipient: (1) a discussion forum, (2) the ability to submit a clinical question through the PCSS website, and (3) one-on-one mentoring.
Posted 3/15/2024 (updated 3/28/2024)
Clinical experts from the Providers Clinical Support System (PCSS) created the Substance Use Disorder 101 Core Curriculum for Healthcare Professionals. With the addition of two new module topics, the 23 modules in this 2023 curriculum provide an overview of evidence-based practices in the prevention, identification, and treatment of substance use disorders and co-occurring medical and psychiatric conditions for a variety of populations.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 5/10/2022 (updated 3/27/2024)
Background: Drug checking uses analytical chemistry technologies to report on the composition of drugs from the unregulated market to reduce substance use-related risks, while additionally allowing for monitoring and reporting of the supply. In the context of an overdose crisis linked to fentanyl, we used drug checking data to examine variability within the illicit opioid supply.